- Led by Edmond Knopp, MD, VP of Medical Affairs

- Welcoming three KOLs to discuss clinical developments in ultra-low-field (ULF) MR imaging

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it will host an analyst and investor education webcast at 2:00 PM Eastern Time on Tuesday, June 25, 2024, focusing on clinical developments in ultra-low-field (ULF) MR imaging.

The event will be moderated by Edmond Knopp, MD, Hyperfine, Inc. VP of Medical Affairs. Dr. Knopp will interview several key opinion leaders on using the Swoop® system in critical care, stroke, and dementia, including Alzheimer’s treatment workflows. The event will conclude with an interactive question and answer session.

Guest Speakers:

• Jamal Derakhshan, MD, PhD, Neuroradiologist and MR Medical Director from Jefferson Abington Hospital, to discuss their experience adopting the Swoop® system.

• W. Taylor Kimberly, MD, PhD, Chief, Division of Neurocritical Care from Mass General Hospital and Associate Professor of Neurology, Harvard Medical School, to discuss using the Swoop® system in acute ischemic stroke triage.

• Cyrus A. Raji, MD, PhD, Director of Neuro Magnetic Resonance Imaging from Barnes Jewish Hospital, Mallinckrodt Institute of Radiology and Associate Professor of Radiology and Neurology Washington University in St. Louis, to discuss imaging needs in dementia and Alzheimer’s care.

A live audio webcast and an archive of the presentation will be available through the Investors page of the Hyperfine, Inc. corporate website at https://investors.hyperfine.io. Participants are encouraged to register more than fifteen minutes before the start of the call.

For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

About the Swoop® Portable MR Imaging® System

​​​​​The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603790628/en/